Publication | Closed Access

Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group

National Cancer InstituteOncologyPhase Ii TrialCancer ManagementPharmacologyClinical TrialsPharmacotherapyCancer TreatmentMedicineLung CancerCancer Research